Panelists discuss how the PERSEUS trial demonstrated superior progression-free survival with daratumumab-VRd compared to VRd alone in patients with transplant-eligible newly diagnosed multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback